HSP90AB1 and triple-negative breast carcinoma: Herein, we show that Hsp90β-selective inhibitors, NDNB1 and NDNB1182, exhibit a moderate selectivity for triple-negative breast cancer (TNBC) over normalized MCF-10A cells in contrast to pan-inhibitors, which do not exhibit a selectivity.